Dr. Nick Pliam is a Venture Partner at Decheng Capital, having joined that firm at its inception in 2011. Trained as an orthopedic surgeon and laboratory scientist, he began his healthcare investment career at Bay City Capital in 2006, focusing on medical technology. At Bay City, Dr. Pliam served on the boards Nevro Corporation (NYSE: NVRO) and IDev Technologies (acquired by Abbott Laboratories). He is currently a director of two China based medical device companies in the Decheng portfolio, Ketai Medical and CardiMED. He received an MD from Dartmouth Medical School and a PhD in Endocrine Physiology from the University of California, San Francisco, following undergraduate studies in German literature at UC Berkeley. Dr. Pliam trained in general surgery at UCSF and completed orthopedic surgical training at Stanford University.